- HealthTech
- Tuesday, 09 Jun 2020
WuXi Biologics Signs Lease for a Clinical Manufacturing Facility in the United States
The new clinical manufacturing facility will install total 6000 L bioreactors, Process Development (PD), Quality Control (QC) labs, along with supporting functions. The 66,000-square-foot facility is expected to become operational in late 2020 and will bring in up to 100 jobs to the region.
This news follows WuXi Biologics' recent purchase of land to build a new 107,000-square-foot clinical and commercial manufacturing facility in Worcester, Massachusetts, and the lease of a 33,000-square-foot site to establish a process development lab in King of Prussia, Pennsylvania.
"We are excited to announce our third site in the United States and proud to become a member of the New Jersey community. Cranbury is a growing hub for the biotech and biopharma industries, and we look forward to working with and serving our partners in the area to benefit patients worldwide," said Dr. Chris Chen, CEO of WuXi Biologics.
Related Industry Updates
Anatomic Pathology Market to Eyewitness Massive Growth by 2026 | Thermo Fisher Scientific, F. Hoffmann-La Roche AG, Abbott
Apr 23, 2021
Latest Report on Asia Pacific Dental X-Ray Market is projected to reach US$ 1,116.80 million by 2027| Business Market Insights
Jan 21, 2021
BMS and Microsoft Expand AI-Powered Radiology for Lung Cancer Detection
Feb 12, 2026
Digital Solutions & Cloud Security Service Transforming Healthcare Industry
May 07, 2020
Asia Pacific Tissue Engineering Market Insights, Deep Analysis of Key Vendor in the Industry 2020 to 2027
Apr 01, 2021
Experimental AI Tool Predicts Which Patients with Pandemic Virus Will Develop Serious Respiratory Disease
Mar 30, 2020
North America Dental Surgery Instruments Market is Rising during 2020-2027 with Top Key Players Like 3M, Danaher, Hu-Friedy Mfg
Apr 22, 2021
Follow us on
